Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

An observational analysis has found that the drugs may lower the risk of substance abuse and cognitive issues. But the ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

Weight-loss medication like Semaglutide and Tirzepatide has seen a rise in demand, causing a boom in sales. This exploding demand has caused many to wonder if they are indeed the magical solution to ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Nationwide research reassures the short-term psychiatric safety of GLP-1 RAs, with no heightened risk observed in patients with psychiatric disorders or obesity. Study: Suicide and suicide attempt ...

MAPD and Part D plans may also cover GLP-1 receptor agonists like liraglutide (Victoza), semaglutide (Wegovy, Ozempic), and dulaglutide (Trulicity). GLP-1 medications can be expensive and may come ...

The launch of Mounjaro always raised the risk that it would cannibalise sales of Lilly's own GLP-1 agonist Trulicity (dulaglutide), which is competing head-to-head with Ozempic in the market ...

Ozempic is squaring off in the market against Eli Lilly’s Trulicity (dulaglutide), which grew 22% to $3.57 billion in the same period. Novo Nordisk also recorded DKK 1 billion ($156 million ...

Available Ozempic alternatives: dulaglutide (generic Trulicity), Metformin, Rybelsus, Wegovy, and Saxenda Keep in mind that location, eligibility criteria, medical history, and drug shortages may ...